Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Benoit You

Showing results (141-150 of 142) with videos related to

Pageof 15
Sort By:
You have reached the last page of results.This site can display upto 142 results.
Bulletin Du Cancer|March 10, 2019
[Management of epithelial ovarian cancer. Short text drafted from the French joint recommendations of FRANCOGYN, CNGOF, SFOG, GINECO-ARCAGY and endorsed by INCa]Vincent Lavoue, Cyrille Huchon, Cherif Akladios, et al.
Lancet (London, England)|June 5, 2025
Relacorilant and nab-paclitaxel in patients with platinum-resistant ovarian cancer (ROSELLA): an open-label, randomised, controlled, phase 3 trialAlexander B Olawaiye, Laurence Gladieff, David M O'Malley, et al.
Pageof 15

Showing results (141-150 of 142) with videos related to

Sort By:
Pageof 15
You have reached the last page of results.This site can display upto 142 results.
Bulletin Du Cancer|March 10, 2019
[Management of epithelial ovarian cancer. Short text drafted from the French joint recommendations of FRANCOGYN, CNGOF, SFOG, GINECO-ARCAGY and endorsed by INCa]Vincent Lavoue, Cyrille Huchon, Cherif Akladios, et al.
Lancet (London, England)|June 5, 2025
Relacorilant and nab-paclitaxel in patients with platinum-resistant ovarian cancer (ROSELLA): an open-label, randomised, controlled, phase 3 trialAlexander B Olawaiye, Laurence Gladieff, David M O'Malley, et al.
Pageof 15